A Benevolent Action
Could harnessing the power of artificial intelligence put an end to the leading cause of sight loss in the developed world?
Maryam Mahdi | | Quick Read
Some have claimed that artificial intelligence (AI) is fast-becoming crucial for the future of pharma. The ability of AI platforms to comb through large and often complex databases using big data analytics is one that many companies are keen to take advantage of for drug discovery. BeneloventAI is one of many AI companies drawing the attention of the industry; its AI platform makes sense of biomedical data via computational and experimental technologies, and the company has become well-recognized for its partnerships with key industry players.
In one of its newest collaborations, BenovolentAI has teamed up with Action Against AMD – a research collaboration formed by four UK sight charities (Blind Veterans UK, Fight for Sight, the Macular Society and Scottish War Blinded). AMD, or age-related macular degeneration, is the leading cause of sight loss in the developed world and exists in two forms; wet and dry. While wet AMD can be treated if diagnosed early, no such treatments exist for the dry form of the condition, leaving patients with a distorted sense of vision and a loss of contrast sensitivity.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.